Marengo Therapeutics and Ipsen have announced that their partnership in cancer research would now encompass Marengo's TriSTAR, a cutting-edge precision T cell engager (TCE) technology. TriSTAR TCEs, derived from Marengo’s proprietary platform, aims to enhance immune responses in ‘cold’ tumors by activating highly activated memory Vβ T cells. This approach seeks to overcome the limitations of traditional TCEs, which often face challenges such as poor T cell quality and exhaustion. Ipsen’s commitment to advancing cancer innovations is bolstered by Marengo’s TriSTAR platform, which holds promise in precisely delivering effective T cell therapies to tumors that typically show limited response to immunotherapies.
Under the terms of the expanded agreement, Ipsen will take over development responsibilities, while Marengo is expected to receive up to $1.2 billion in milestone payments and sizable upfront payments and royalties on sales. Ipsen, a global biopharmaceutical leader with a robust pipeline in oncology and other therapeutic areas, underscores its dedication to leveraging external innovation to deliver transformative medicines. Marengo Therapeutics, a clinical-stage biotech company specializing in TCR-targeting antibodies, continues to advance its STAR platform, aiming to revolutionize cancer treatment through enhanced immune system activation.
